Trial Profile

A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Napabucasin (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America

Most Recent Events

17 Jul 2020 Status changed from active, no longer recruiting to completed.
01 Jul 2020 According to a Sumitomo Dainippon Pharma Oncology media release, the Boston Biomedical has been merged with the Tolero Pharmaceuticals to form the Sumitomo Dainippon Pharma Oncology.
25 Mar 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com